Migraine

Survey finds that 91% of health care providers and 67% of people with migraines feel that individuals who are able to successfully manage stress and mental health conditions can also better manage the symptoms of migraine.

Researchers highlight how a lack of access to medications used to treat multiple sclerosis, migraines, and epilepsy, but not proven safe for pregnancy, threatens child-bearing aged women who live with these conditions.

The submission is based on 2 pivotal phase 3 studies evaluating the drug in adult patients with chronic and episodic migraines.

A study demonstrated the role of the serotonin 1B receptor in appetite and showed that triptan, a commonly prescribed migraine medicine, may be repurposed for appetite suppression and obesity.

Triptans are contraindicated in patients with ischemic heart disease, cerebrovascular disease, uncontrolled hypertension, and peripheral artery disease.

Patients with refractory chronic migraine experience short- and medium-term pain relief and minimal adverse drug effects from lidocaine infusions.

Migraine Be KoooL is intended to provide relief from headaches, fever, muscle aches, sprains, and over-exertion.

Investigators studied the efficacy and safety of eptinezumab-jjmr in the 100 mg and 300 mg intravenous infusion dosages in individuals with 2 to 4 documented unsuccessful prior preventive treatment failures for migraine in the past 10 years.

Submission is based on phase 2 study results evaluating atogepant in adults who met the primary endpoint of a statistically significant reduction from the baseline compared with a placebo.

Migraines can have a high cost for the health care system overall, with an estimated $1 billion dollars or more spent in indirect and direct costs.

Options include calcitonin gene-related peptide antagonists, ergotamine, hormone therapy, lasmiditan, and triptans.

Real-world data show fremanezumab-vfrm (Ajovy) injection plus gepants combination effective in patients with difficult-to-treat migraine.

The increased negative health outcomes associated with migraines provide an opportunity for pharmacists in both the inpatient and outpatient setting to support patients.

Researchers found a significant decrease in cortical silent period duration after sleep restriction in patients with interictal migraine compared to controls.

Analysis finds that reported adverse events rarely led to the discontinuation of therapy when used as a migraine prophylaxis.

Lifestyle-related factors, including food consumption, may significantly increase the chance of triggering a migraine headache.

Nonprescription migraine pain reliever combines acetaminophen, aspirin, and caffeine to relieve migraine pain.

Pharmacists can potentially improve the health and quality of life of millions of people by staying up to date with advancements in migraine treatments.

Fremanezumab is the second FDA-approved preventive migraine treatment that blocks the activity of calcitonin gene-related peptide.

Eptinezumab is a calcitonin gene-related peptide antagonist FDA-approved for the preventive treatment of migraine.

Study results show that an individual received little or no relief from doing yoga, eliminating certain foods, practicing medication, or taking prescribed medications.

Patients in the atogepant 60 mg daily and 30 mg twice daily treatment arms of the study experienced a decrease of 6.88 and 7.46 monthly migraine days, respectively.

Previous research has shown that genetic factors contribute immensely to the risk of migraine.

Galcanezumab-gnlm (Emgality) is indicated in adults for the preventive treatment of migraine and treatment of episodic cluster headache.

Analysis assessing data from the world’s largest twin registry also finds evidence that genetic factors for strong headaches may differ between men and women.

Headache disorders most affect the ability to do physical labor, decision-making skills, and memory, investigators from the University of Copenhagen say.

Although the risks are still, individuals with a history of migraines should be aware of and consult with their physicians, investigators say.

Pharmacists must understand the value of monitoring changes in quality of life and headache frequency to help facilitate the decision to continue, discontinue, or restart migraine prophylaxis.

Erenumab (Aimovig) was the first anti-CGRP agent approved by the FDA for migraine prophylaxis.